Dynamic Changes in Soluble Interleukin-2 Receptor Levels during Treatment of Graves’ Disease
| Autor: | B. Gobert, Georges Weryha, J Leclère, Gilbert C. Faure, Pierre Hartemann, Marie-Christine Béné |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Autoimmune disease
Interleukin 2 medicine.medical_specialty Triiodothyronine business.industry Endocrinology Diabetes and Metabolism Antithyroid agent medicine.medical_treatment Graves' disease medicine.disease medicine.disease_cause Autoimmunity Endocrinology Carbimazole Internal medicine medicine business Receptor medicine.drug |
| Zdroj: | Hormone Research. 35:8-12 |
| ISSN: | 1423-0046 0301-0163 |
| DOI: | 10.1159/000181868 |
| Popis: | The activation of T lymphocyte is accompanied by the release of soluble interleukin-2 receptors (sIL-2R) which can be assessed in biological fluids. A prospective study of the dynamic changes in sIL-2R levels was performed in the serum of 10 patients undergoing a medical treatment for Graves’ disease. All patients received carbimazole during the study and, when necessary, L-thyroxine to compensate hypothyroidism. sIL-2R levels were measured before (M0) and after the 1st (M1), 3rd (M3) and 6th month (M6) of treatment. The levels of sIL-2R were high at MO and Ml, and decreased significantly between Ml and M3 (p = 0.03). At MO, the levels of sIL-2R were highly correlated with triiodothyronine (T3) levels (p = 0.0003), early [131I] uptake (p = 0.007) and, to a lesser degree, with anti-thyrotropin receptor antibody levels (p = 0.02). At M6, no correlation was found anymore. We conclude that sIL-2R levels are increased in patients with untreated Graves’ disease. They are highly correlated with the markers of Graves’ disease activity and decrease during medical treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|